Eran Steinberg is a serial entrepreneur, prolific inventor, and IP strategist who co-founded FotoNation in 1997 - selling it, buying it back, and doing it again a third time. Best known for pioneering the automatic red-eye removal technology now standard in virtually every digital camera and smartphone on earth, he holds 300+ patents across imaging, medical devices, and drug development. A licensed USPTO patent agent with four graduate and undergraduate degrees - including both a B.F.A. in Fine Art Photography and an M.S. in Imaging Science - he bridges the worlds of deep technology and creative vision. Currently CEO and Chairman of Vaica Medical and Chairman of FotoNation following a third management buyout, he also lectures at Johns Hopkins University.
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.